|
Daily Medical Update
Upper gastrointestinal hemorrhage
Wednesday, October 07, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Endoscopy (2026) - Practice Guideline
Key Findings
- For high-risk peptic ulcer bleeding, over-the-scope clips are suggested as monotherapy to reduce further bleeding risk compared with standard endoscopic hemostasis.
- For persistent or recurrent bleeding refractory to endoscopic therapy, escalation to topical agents or over-the-scope clips and then transcatheter angiographic embolization is recommended to reduce ongoing hemorrhage; surgery is reserved for failed or unavailable embolization.
📋 Practice Implication: Use the updated ESGE pathway to reserve the most advanced rescue options for refractory or recurrent bleeding while avoiding routine emergent endoscopy after adequate resuscitation.
|
PeerJ (2026) - Systematic Review
Key Findings
- Ultra-early endoscopy did not significantly reduce mortality (OR 0.88, 95% CI 0.58-1.34) or rebleeding (OR 1.23, 95% CI 0.90-1.67) compared with endoscopy after 6 hours.
- ICU admission was increased with ultra-early endoscopy (OR 1.41, 95% CI 1.20-1.66), while transfusion, surgery, repeat endoscopy, and hospital length of stay did not differ significantly.
📋 Practice Implication: Prioritize hemodynamic stabilization and a timely therapeutic window rather than automatically targeting endoscopy within 6 hours in clinically stable nonvariceal bleeding.
|
Gut (2025) - Randomized Controlled Trial
Key Findings
- After initial endoscopic hemostasis, 72-hour rebleeding was reduced with Nexpowder versus no further therapy (2.9% vs 11.3%; p = 0.005).
- The 30-day cumulative rebleeding rate was also reduced (7.0% vs 18.8%), and no adverse events related to powder application were reported.
📋 Practice Implication: Consider Nexpowder as an adjunct after successful hemostasis in selected high-risk nonvariceal lesions when early and late rebleeding prevention is a priority.
|
Expert review of hematology (2026) - Randomized Controlled Trial
Key Findings
- At 72 hours, restrictive transfusion improved coagulation findings, with higher fibrinogen and platelet levels, shorter activated partial thromboplastin, prothrombin, and thrombin times, and higher 24-hour hemostasis rates than liberal transfusion.
- Restrictive transfusion reduced per-patient transfusion volume, adverse events, and rebleeding compared with the liberal strategy.
📋 Practice Implication: A restrictive transfusion approach may improve early hemostatic physiology while limiting transfusion exposure, but the single-center design warrants cautious adoption alongside standard clinical thresholds.
|
Digestive diseases (Basel, Switzerland) (2026) - Network Meta-Analysis
Key Findings
- Erythromycin plus nasogastric lavage ranked highest for adequate visualization (RR 2.49, 95% CI 1.57-3.95), followed by erythromycin alone (RR 2.24, 95% CI 1.56-3.21).
- Erythromycin improved visualization scores (SMD 0.86, 95% CI 0.36-1.36), but no significant differences were found in endoscopy duration or 24-hour transfusion requirements.
📋 Practice Implication: Use erythromycin, with nasogastric lavage when appropriate, to improve the endoscopic field; do not assume that better visualization alone reduces transfusion needs or procedure time.
|
|
💡
Summary
Recent high-significance evidence supports resuscitation followed by timely, rather than routinely ultra-early, endoscopy for nonvariceal upper gastrointestinal bleeding. Adjunctive haemostatic powder reduced early and 30-day rebleeding after primary haemostasis, while restrictive transfusion improved short-term coagulation and hemostasis outcomes. Prokinetic therapy, especially erythromycin with or without nasogastric lavage, improved endoscopic visualization, although patient-centered benefits beyond visualization remain uncertain.
|
|